DMRA
Damora Therapeutics, Inc.
NASDAQ: DMRA · HEALTHCARE · BIOTECHNOLOGY
$25.36
-1.17% today
Updated 2026-05-01
Market cap
$1.46B
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-3.98
Dividend yield
—
52W range
$2 – $38
Volume
0.3M
Damora Therapeutics, Inc. (DMRA) Financial statements
SEC filings — annual and quarterly data.
Cash flow — annual
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $-13.69M | $-19.33M | $-38.20M | $-52.31M | $-42.93M | $-36.91M | $-18.62M | $-6.73M |
| Capital expenditures | $0.00 | $0.00 | $0.00 | $223000.00 | $196000.00 | $0.00 | $0.00 | $0.00 |
| Depreciation | — | — | — | — | — | — | — | — |
| Stock-based comp | — | — | — | $4.48M | $5.57M | $5.43M | $3.24M | $998000.00 |
| Free cash flow | $-13.69M | $-19.33M | $-38.20M | $-52.53M | $-43.13M | $-36.91M | $-18.62M | $-6.73M |
| Investing cash flow | — | — | — | — | — | — | — | — |
| Financing cash flow | — | — | — | — | — | — | — | — |
| Dividends paid | — | — | — | — | — | — | — | — |
| Share repurchases | — | — | — | — | — | — | — | — |
| Debt repayment | — | — | — | — | — | — | — | — |
| Net change in cash | — | — | — | — | — | — | — | — |